© 1992 Oxford University Press
research-article |
Relationship of Blood Prolactin Levels and the Risk of Subsequent Breast Cancer
*Clinical Endocrinology Laboratory, Imperial Cancer Research Fund, Guy's Medical School Guy's Campus, London SE1 9RT, UK
**Medical Statistics Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields London WC2A 3PX, UK
University of Glasgow, Department of Surgery, Western Infirmary Glasgow G11 6NT, UK
Antoni van Leeuwenhoekhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
§Clinical Oncology Unit Guy's Campus, London SE1 9RT, UK
Between 1968 and 1976 a total of 5162 women volunteers were enrolled into a prospective study conducted on the Island of Guernsey. Up to February 1990 145 women subsequently developed breast cancer. Blood samples were taken at the time of enrollment and prolactin levels were known for 85% of the volunteers. In calculating the relationship between blood prolactin levels and subsequent breast cancer risk, women were excluded if they had a hysterectomy or an oophorectomy or had cancer at any site before enrollment. The final analysis was based on 2596 premenopausal and 1180 naturally postmenopausal women and, of these respectively, there were 71 and 40 volunteers who subsequently developed breast cancer. The total follow-up for these two groups was 49941 and 22360 woman-years, respectively.
In assessing the relationship between blood prolactin levels and risk of subsequent breast cancer the cohort was divided into quintiles according to prolactin concentration and relative risks (RR) were estimated. In calculating these values possible confounding by age at entry, age at menarche, parity, age at first birth, years since menopause, body build, history of benign breast disease and family history of breast cancer were taken in to consideration.
There was no significant relation between risk of breast cancer and prolactin in either pre- or postmenopausal women. Hence prolactin appears not to be an important determinant of breast cancer risk.
Received 1 September 1991
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. W. Harvey, D. J. Everett, and C. J. Springall Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol, March 1, 2008; 22(2 Suppl): 20 - 27. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, A. H. Eliassen, P. Sluss, and S. E. Hankinson A Prospective Study of Plasma Prolactin Concentrations and Risk of Premenopausal and Postmenopausal Breast Cancer J. Clin. Oncol., April 20, 2007; 25(12): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P W Harvey, D J Everett, and C J Springall Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer Human and Experimental Toxicology, July 1, 2006; 25(7): 395 - 404. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, P. Sluss, and S. E. Hankinson Association between Plasma Prolactin Concentrations and Risk of Breast Cancer among Predominately Premenopausal Women Cancer Res., February 15, 2006; 66(4): 2476 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Albrektsen, I. Heuch, S. Thoresen, and G. Kvale Clinical Stage of Breast Cancer by Parity, Age at Birth, and Time Since Birth: A Progressive Effect of Pregnancy Hormones? Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Pinheiro, M. D. Holmes, M. N. Pollak, R. L. Barbieri, and S. E. Hankinson Racial Differences in Premenopausal Endogenous Hormones Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2147 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, A. H. Eliassen, B. Rosner, P. Sluss, and S. E. Hankinson Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer Cancer Res., September 15, 2004; 64(18): 6814 - 6819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bernichtein, C. Kayser, K. Dillner, S. Moulin, J. J. Kopchick, J. A. Martial, G. Norstedt, O. Isaksson, P. A. Kelly, and V. Goffin Development of Pure Prolactin Receptor Antagonists J. Biol. Chem., September 19, 2003; 278(38): 35988 - 35999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler The Role of Prolactin in Mammary Carcinoma Endocr. Rev., February 1, 2003; 24(1): 1 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Allen, G. T. H. Ellison, I. dos Santos Silva, B. L. De Stavola, and I. S. Fentiman Determinants of the Availability and Accuracy of Self-reported Birth Weight in Middle-aged and Elderly Women Am. J. Epidemiol., February 15, 2002; 155(4): 379 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Glasow, L.-C. Horn, S. E. Taymans, C. A. Stratakis, P. A. Kelly, U. Kohler, J. Gillespie, B. K. Vonderhaar, and S. R. Bornstein Mutational Analysis of the PRL Receptor Gene in Human Breast Tumors with Differential PRL Receptor Protein Expression J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3826 - 3832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Hankinson, W. C. Willett, D. S. Michaud, J. E. Manson, G. A. Colditz, C. Longcope, B. Rosner, and F. E. Speizer Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, April 7, 1999; 91(7): 629 - 634. [Abstract] [Full Text] [PDF]
|
|